Harvard Scientists Reversed Aging in Human Cells With Chemicals Alone — and Now They're Testing It in People

Petri dish with activity

Old cells, made young again, in under a week. That was the headline in July 2023, when a team at Harvard Medical School led by David Sinclair reported that six chemical cocktails could reset aging human cells to a younger state — no gene therapy required. It was one of the most talked-about aging studies of the decade. Three years later, the story has moved further than most people realize: the first human trial of age reversal began in 2026.

Can scientists actually reverse aging human cells in trials? Are we on the cusp of a breakthrough in human longevity and aging?

Here is what the original study actually showed, what has happened since, and what is still unproven.

What the Harvard Team Did in 2023

Until this study, rewinding a cell's age meant gene therapy. Scientists used the Yamanaka factors — a set of genes that can reset an adult cell toward a stem-cell-like state — to push old cells back toward youth. It worked in animals, but gene therapy is expensive, complicated, and hard to roll out widely. Sinclair's team asked a different question: could chemicals alone do the same job?

The answer, in a dish at least, was yes. The researchers screened combinations of small molecules and identified six chemical cocktails that, in less than a week, restored youthful gene-expression patterns in cultured human fibroblasts, including senescent cells that had stopped dividing. The treated cells showed a younger transcriptomic age and improved organization of proteins between the nucleus and the rest of the cell. Critically, the cells kept their identity — they got younger without turning into stem cells or something else entirely.

The strongest recipe, known as VC6TF, combined five compounds: valproic acid, CHIR-99021, E-616452 (also called RepSox), tranylcypromine, and forskolin. The findings were published in the journal Aging on July 12, 2023. Sinclair's comment at the time captured the ambition: the best science could do before was slow aging, and now, he believes, we can reverse it — maybe one day with a single pill.

What the 2023 Study Did Not Prove

This is the part that often gets left out of the headlines, and it matters. The experiments were done in cultured cells, not in animals or people. No animals were treated with these exact cocktails and shown to live longer or function better. No humans were treated at all.

Other scientists urged caution. Biogerontologist Matt Kaeberlein said publicly that claims of a chemical approach that reverses aging overstated the data, arguing that nobody has a drug that reverses aging. Others pointed out that several of the molecules have known toxicity: valproic acid carries a black-box warning, and tranylcypromine is a monoamine oxidase inhibitor with dietary and drug-interaction restrictions. There is no commercial product that delivers the published cocktails at the concentrations used in the cell studies, and no one should try to assemble them on their own.

A 2025 paper from another lab simplified the idea further, reducing a related chemical approach to just two molecules, RepSox and tranylcypromine. The field is moving, but the 2023 result remains what it was: a promising lab finding, not a treatment.

The Big Update: the First Human Trial Began in 2026

The most important development since the paper is not about the cocktails at all. It is about the gene-therapy side of the same science. In January 2026, the FDA cleared Life Biosciences, a company co-founded by Sinclair, to begin the first human clinical trial of partial epigenetic reprogramming. The treatment, called ER-100, is a gene therapy that briefly switches on three reprogramming genes — Oct4, Sox2, and Klf4, known as OSK — in the eye.

The trial targets two age-related vision diseases: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, or NAION, essentially a stroke of the optic nerve. Up to 18 participants, ages 40 to 85, will receive a single injection of a harmless viral vector carrying the OSK genes into one eye. The genes stay silent until the patient takes the antibiotic doxycycline as a daily pill for about eight weeks, which flips the switch on. Stop the pill, and the factors switch off again.

The first participant was dosed on June 9, 2026. On October 8, 2026, the company reported interim data from the first three glaucoma patients: the lowest dose was well tolerated through 56 days, and the safety board recommended escalating the dose. The company also reported preliminary visual-field improvements in two of the three patients. Those are company-reported results from three people in an open-label safety trial — encouraging, but not proof of anything yet. The trial's primary goal is safety, not proving that aging can be reversed. No efficacy results have been released beyond that early report, and the company expects enough data by the end of 2026 to decide on a Phase 2 trial.

The Pill Dream Is Still Alive — and Still Unproven

Sinclair has not given up on the chemical route. In a September 2026 appearance on The Joe Rogan Experience, he described unpublished experiments in his lab, including work toward a drink that rejuvenates mice, and a collaboration using AI to search roughly 10 billion possible molecules for a single compound that could replace a whole reprogramming cocktail. About 200 candidates have been narrowed down for testing in human cells. He also mentioned work on restoring lost memories in mice, though that research is unpublished.

Separately, Sinclair's team is pursuing an oral small-molecule cocktail, referred to as SL-100, aimed at whole-body rejuvenation through the bloodstream, with the $101 million XPRIZE Healthspan competition as its proving ground. If the eye trial works, the company has said it plans to expand toward hearing loss, liver and lung disease, muscle wasting, and neurodegenerative diseases.

What This Means Right Now

The honest summary is this: the 2023 chemical cocktails showed that features of cellular aging can be chemically reversed in a dish, in under a week, without gene therapy and without erasing a cell's identity. That was real, peer-reviewed science. In 2026, the first human test of the related gene-therapy approach began, and its earliest safety data looks clean so far. But no approved epigenetic reprogramming therapy exists, no chemical cocktail has been tested in people, and no pill can reverse your age today.

The next 12 to 24 months will tell the story. If the eye trial proves safe and shows real vision benefits, the field moves from lab dishes to medicine. If it does not, the 2023 paper remains an intriguing result that never left the petri dish. Either way, the idea that aging might be reversible — not just slowable — is no longer science fiction. It is in human testing, one eye at a time.

Sources

Yang JH, Petty CA, Dixon-McDougall T, et al. "Chemically induced reprogramming to reverse cellular aging." Aging, July 12, 2023. Life Biosciences / ClinicalTrials.gov, trial NCT07290244 (ER-100 Phase 1/2A, first participant dosed June 9, 2026; interim data October 8, 2026). Medical Daily, "The First Human Trial to Reverse Aging Just Got FDA Clearance," July 13, 2026. NAD.com, David Sinclair update on The Joe Rogan Experience, September 2026.